Sonic Healthcare Limited
SHL
Kedudukan dalam Saham
#2850
Sonic Healthcare Limited delivers medical diagnostic services to a diverse... Sonic Healthcare Limited delivers medical diagnostic services to a diverse clientele, including medical professionals, hospitals, public health organizations, and individual patients. The company's services encompass a broad spectrum of laboratory medicine and pathology testing, covering biochemistry, cytopathology, genetics, haematology, histopathology, immunoserology, microbiology, molecular pathology, prenatal diagnostics, toxicology, and other related functions. Furthermore, Sonic provides extensive radiology services, such as magnetic resonance imaging (MRI), computed tomography (CT), ultrasound, X-ray, mammography, nuclear medicine, PET CT, interventional procedures, and bone mineral densitometry. Its offerings also extend to primary care medical services, featuring general practice clinics, occupational health, specialized skin cancer clinics, after-hours GP services, IT solutions for general practices, and various community-based healthcare programs. Operating internationally, the company has a significant presence in Australia, the United Kingdom, Ireland, the United States, Germany, Switzerland, New Zealand, and Belgium. Founded in 1934, Sonic Healthcare Limited is headquartered in Sydney, Australia.
Harga Saham
$13.25
Modal Pasaran
$6.55B
Perubahan (1 hari)
-0.29%
Perubahan (1 tahun)
-4.56%
Negara
AU
Perdagangan Sonic Healthcare Limited (SHL)
Kategori
Healthcare
Nisbah P/E bagi Sonic Healthcare Limited (SHL)
Nisbah P/E pada October 2026 TTM: 15.03
Menurut laporan kewangan dan harga saham terkini Sonic Healthcare Limited, nisbah P/E semasa (TTM) ialah 15.03. Pada akhir 2024, syarikat mempunyai nisbah P/E sebanyak 23.90.
Sejarah nisbah P/E bagi Sonic Healthcare Limited dari 2000 hingga 2026
Nisbah P/E pada akhir setiap tahun
| Tahun | Nisbah P/E | Ubah |
|---|---|---|
| 2026 (TTM) | 15.03 | -40.13% |
| 2025 | 25.11 | 5.04% |
| 2024 | 23.90 | -2.01% |
| 2023 | 24.39 | 125.74% |
| 2022 | 10.81 | -22.48% |
| 2021 | 13.94 | -49.09% |
| 2020 | 27.38 | 23.57% |
| 2019 | 22.16 | 1.75% |
| 2018 | 21.78 | -7.71% |
| 2017 | 23.59 | 20.42% |
| 2016 | 19.59 | -20.58% |
| 2015 | 24.67 | 36.98% |
| 2014 | 18.01 | 5.52% |
| 2013 | 17.07 | 8.95% |
| 2012 | 15.67 | -7.69% |
| 2011 | 16.97 | 22.94% |
| 2010 | 13.81 | -47.44% |
| 2009 | 26.27 | 35.39% |
| 2008 | 19.40 | -14.15% |
| 2007 | 22.60 | -4.90% |
| 2006 | 23.77 | -108.30% |
| 2005 | -286.19 | -96.99% |
| 2004 | -9.51K | -615.14% |
| 2003 | 1.85K | 142.10% |
| 2002 | 762.85 | -97.48% |
| 2001 | 30.27K | -9,768.14% |
| 2000 | -313.13 | 0.00% |
Nisbah P/E untuk syarikat serupa atau pesaing
| Syarikat | Nisbah P/E | Perbezaan Nisbah P/E | Negara |
|---|---|---|---|
| 36.15 | 140.51% |
US
|
|
| 39.77 | 164.58% |
US
|
|
| -290.26 | -2,030.87% |
US
|
|
| - | - |
CN
|
|
| 34.18 | 127.41% |
US
|
Cara membaca nisbah P/E
Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.
Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.
Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.